{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:17:15Z","timestamp":1787505435166,"version":"build-2736575974"},"reference-count":13,"publisher":"Japanese Society of Internal Medicine","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,6,15]]},"DOI":"10.2169\/internalmedicine.4498-24","type":"journal-article","created":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T17:12:56Z","timestamp":1732122776000},"page":"1884-1887","source":"Crossref","is-referenced-by-count":4,"title":["Quantifying the Reversibility of Clofazimine-induced Pigmentation in a Patient with &lt;i&gt;Mycobacterium abscessus&lt;\/i&gt; Pulmonary Disease"],"prefix":"10.2169","volume":"64","author":[{"given":"Masashi","family":"Ito","sequence":"first","affiliation":[{"name":"Respiratory Disease Center, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Japan"},{"name":"Department of Clinical Mycobacteriosis, Nagasaki University Graduate School of Biomedical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiya","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Pharmacometrics and Pharmacokinetics, Meiji Pharmaceutical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Furuuchi","sequence":"additional","affiliation":[{"name":"Respiratory Disease Center, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Fujiwara","sequence":"additional","affiliation":[{"name":"Respiratory Disease Center, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Japan"},{"name":"Department of Basic Mycobacteriosis, Nagasaki University Graduate School of Biomedical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Kodama","sequence":"additional","affiliation":[{"name":"Respiratory Disease Center, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Japan"},{"name":"Department of Basic Mycobacteriosis, Nagasaki University Graduate School of Biomedical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ohe","sequence":"additional","affiliation":[{"name":"Respiratory Disease Center, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Respiratory Disease Center, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Yoshiyama","sequence":"additional","affiliation":[{"name":"Respiratory Disease Center, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Ohta","sequence":"additional","affiliation":[{"name":"Respiratory Disease Center, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kozo","family":"Morimoto","sequence":"additional","affiliation":[{"name":"Respiratory Disease Center, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Japan"},{"name":"Department of Clinical Mycobacteriosis, Nagasaki University Graduate School of Biomedical Sciences, Japan"},{"name":"Division of Clinical Research, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Marras TK, Nelson P, Peci A, et al. Pulmonary nontuberculous mycobacteria, Ontario, Canada, 2020. Emerg Infect Dis 29: 1415-1419, 2023.","DOI":"10.3201\/eid2907.230216"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Fujiwara K, Furuuchi K, Aono A, et al. Clinical risk factors related to treatment failure in <i>Mycobacterium abscessus<\/i> lung disease. Eur J Clin Microbiol Infect Dis 40: 247-254, 2021.","DOI":"10.1007\/s10096-020-04026-z"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline. Clin Infect Dis 71: e1-e36, 2020.","DOI":"10.1093\/cid\/ciaa241"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Watanabe F, Furuuchi K, Hanada K, et al. Pharmacokinetics and adverse effects of clofazimine in the treatment of pulmonary non-tuberculous mycobacterial infection. Antimicrob Agents Chemother 66: e0044122, 2022.","DOI":"10.1128\/aac.00441-22"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. World Health Organization. The final push strategy to eliminate leprosy as a public health problem: questions and answers. Lepr Rev 73: 279-281, 2002.","DOI":"10.47276\/lr.73.3.279"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Watanabe F, Fujiwara K, Furuuchi K, et al. Clofazimine serum concentration and safety\/efficacy in nontuberculous mycobacterial pulmonary disease treatment. Respir Med 231: 107718, 2024.","DOI":"10.1016\/j.rmed.2024.107718"},{"key":"7","unstructured":"7. Osuji Y, Omatsu J, Yoshizaki A, Sato S. [Assessment of Skin Aging Using NeoVoir]. Aesthetic Dermatology 33: 264, 2023."},{"key":"8","unstructured":"8. Woods GL, Brown-Elliott BA, Conville PS, et al. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes, 2nd ed. Clinical and Laboratory Standards Institute, Wayne, PA, 2011."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Kurahara Y, Tanaka Y, Kobayashi T, Yoshida S, Tsuyuguchi K. Changes in skin discoloration according to clofazimine dosage in nontuberculous mycobacterial pulmonary disease. J Infect Chemother 31: 102441, 2025.","DOI":"10.1016\/j.jiac.2024.06.004"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. vanIngen J. Why do we use 100 mg clofazimine for TB and NTM treatment? J Antimicrob Chemother 79: 697-702, 2024.","DOI":"10.1093\/jac\/dkae041"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Kwak N, Whang J, Yang JS, Kim TS, Kim SA, Yim JJ. Minimal inhibitory concentration of clofazimine among clinical isolates of nontuberculous mycobacteria and its impact on treatment outcomes. Chest 159: 517-523, 2021.","DOI":"10.1016\/j.chest.2020.07.040"},{"key":"12","unstructured":"12. Sandler ED, Ng VL, Hadley WK. Clofazimine crystals in alveolar macrophages of a patient with acquired immunodeficiency syndrome. Arch Pathol Lab Med 116: 541-543, 1992."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Wu Q, Ganzert C, L\u00fccke E, Bittmann I, Schreiber J. Fatal course of clofazimine-induced pulmonary crystal deposition in a patient with Melkersson-Rosenthal syndrome. Int J Clin Pharmacol Ther 58: 518-522, 2020.","DOI":"10.5414\/CP203784"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/12\/64_4498-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T23:59:03Z","timestamp":1750463943000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/12\/64_4498-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,15]]},"references-count":13,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4498-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,15]]},"article-number":"4498-24"}}